ANGLE Ventures

ANGLE has founded and developed a portfolio of companies in which it retains substantial equity stakes. These companies were selected for their strong IP platform addressing a large international market providing the potential for exceptional investment returns for ANGLE shareholders.

The portfolio spans medical and life sciences through to IT and software with the base intellectual property sourced from world class research establishments such as Dstl (UK Defence Science & Technology Laboratory), the Universities of Bristol, Cambridge and York and the Rowett Institute (Europe's leading nutrition research Institute) and in the US from the Universitites of Southern California and New York.

The average age of the portfolio companies is six years old and they have been developed to the stage where, with the exception of Parsortix,  the portfolio is substantially cash-independent of ANGLE, thereby presenting ANGLE shareholders with the potential for substantial upside returns without a corrresponding downside risk of further investment.

Over the last two years, ANGLE has deployed a deliberate strategy to focus its efforts and resources on the winners within the portfolio recognising that, with early stage technology investment, successful returns are likely to be concentrated in a relatively small number of investments, which may be big winners.

ANGLE has principal holdings, which it currently considers have the potential to provide exceptional returns to ANGLE shareholders.